Introduction
For more than 70 years, bacterial infections and, more recently, parasitic, fungal and viral infections have benefited from therapeutic substances of natural, semisynthetic or synthetic origin. However, all causative microorganisms have revealed a remarkable ability to adapt, to evolve, and to survive by developing resistance to each and every therapeutic compound administered.
At first, resistant strains were considered simply to be a local and undesirable side effect of the treatment, but it is now clear that they reflect a profound change in our environment. These resistant strains have proved to be global, and extremely dangerous. Bacterial resistance to antimicrobials has been most extensively studied in the context of the number of antimicrobials used to satisfy the needs of human and animal health.
Antifungal drug resistance is a clinically important and emerging subject, especially in human medicine, but less so in livestock. Standardised methods for reliable in vitro antifungal susceptibility testing are now available from the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing. Studies are expanding on azoles and echinocandins, as well as on the epidemiology of fungal infections. Antiviral compounds, although rarely used in foodproducing animals, have had an enormous beneficial impact on human diseases, particularly the human immunodeficiency virus/acquired immune deficiency syndrome complex and influenza. Information about the use of antiviral compounds in veterinary medicine can be found in Box 1.
Parasitic infections in humans and domestic animals, which increasingly involve resistant strains, are a significant problem worldwide. A number of types of human parasitosis have been classified as 'neglected diseases', often associated with poor levels of diagnosis, surveillance and management. The incidence of parasitic infection has often been misinterpreted, and in many cases there has been no reliable method to study parasite resistance to therapeutic agents.
Anthelmintic resistance in nematode and trematode parasites of ruminants is an important global issue.
Resistance in protozoal infections, including coccidiosis of poultry, is now observed. This subject deserves greater study in humans and other animals, recognising that many antiprotozoal agents have antibacterial activity as well. In specific areas work is already well advanced. For example, the management of resistant malaria is one of the priorities of the World Health Organization.
However, this special issue of the OIE Scientific and Technical Review, focuses principally on the topic of
Box 1 The use of antiviral compounds in veterinary medicine
The world of viruses is vast and highly complex. Although the number of viral species has previously been estimated at around 5,000, this is a gross underestimation.
Two extensively studied species of mammal are humans and cattle; humans are known to host eight different species of herpes virus and cattle five. If we consider that these two species alone host thirteen different identified herpesviruses we get a clearer picture of the extraordinary number of different viruses that must exist in the animal kingdom as a whole. Even if we take into account only vertebrate species (5,416 mammals, 9,723 birds, 9,002 reptiles, 6,570 amphibians and 31,564 fish) it becomes apparent that the total number of viruses among all animal species is huge.
The 1,415 pathogens identified in humans include 217 viruses and prions, 538 bacteria and rickettsiae, 307 fungi, 66 protozoa and 287 helminths. Of these pathogens, 868 (61%) are considered to be zoonotic and 175 to be associated with emerging diseases. Of the 175 agents responsible for emerging infections in humans, 132 (75%) are zoonotic and most have originated in wildlife, emphasising the role of wildlife as a potential source of new emerging diseases, especially viral infections.
The number of viral species identified in humans is also a good indicator of the scale of the virus domain. A key feature of viruses is their extreme variability. In particular, RNA viruses, multi-segmented or not, show great diversity that results from the lack of an error-correction mechanism for use during nucleic acid replication. This variability is underpinned by an exceptionally high mutation rate such that, in a viral RNA genome of around 8,000 nucleotides, all progeny viruses that result from multiplication differ from the parental strain by at least one nucleotide. This exceptional mutation rate leads to the formation of populations of quasi-species.
In the absence of broad-spectrum antivirals, a number of methods have been successful in controlling viral diseases in animals. For production animals they include preventive hygiene measures to avoid possible contamination, disinfection, stamping out (culling) and vaccination.
The most resounding success story in animal health has been the use of routine cattle vaccination to eradicate rinderpest, which is caused by a morbillivirus. In 2011, the World Organisation for Animal Health and the Food and Agriculture Organization of the United Nations declared rinderpest to have been officially eradicated.
A range of measures is also used to tackle other viral infections, the most dreaded of which are legally notifiable transboundary diseases, including foot and mouth disease, classical swine fever, avian influenza (highly pathogenic avian influenza in birds and low-pathogenicity notifiable avian influenza in poultry) and rabies. These measures can even be applied to wildlife, for example, wild carnivores can be vaccinated against rabies or wild boars against classical swine fever.
Experimental therapeutic trials of antiviral drugs have also been conducted, such as a trial of interferon alpha in cattle.
In the absence of effective vaccines (e.g. against African swine fever) and in the presence of newly emerging zoonotic diseases (e.g. Nipah virus infection in pigs), stamping out is often the only choice.
The control of major viral diseases is currently facilitated by the availability of DIVA (differentiating infected from vaccinated animals) vaccines, which allow serological differentiation between animals that have only been vaccinated and those that are infected (whether or not they have been vaccinated).
Although vaccination is the first priority for controlling viral infections in companion animals (except in special situations, such as to control stray dogs, which are potential carriers of rabies), some antiviral drugs are used therapeutically. Only one antiviral compound has been granted a marketing authorisation in Europe: feline omega interferon, which was originally developed for the treatment of canine parvovirus infection. Other drugs approved for humans are also used in veterinary medicine, in accordance with the cascade principle; for example, zidovudine is used to treat feline immunodeficiency virus infection. There are a number of obstacles to the development of antivirals for animals: the high development cost; the often very narrow specificity of the viral target; the diversity of animal species concerned; and the difficulty of developing low-toxicity broadspectrum molecules. Viruses are obligate cellular parasites and non-selective toxicity is an issue of paramount importance.
In conclusion, antivirals currently play a very limited role in animal health and if their use were to become widespread, resistance would be expected to emerge rapidly because of the exceptionally high mutation rate of viruses, particularly RNA viruses. Even dealing with this limited topic has been a challenge. Antimicrobial resistance is a complex phenomenon, especially in veterinary medicine, because of the number of animal species, the diversity of rearing environments, the differences in the bacteria involved, the range of pathogenicity mechanisms and the complex epidemiology. A number of antimicrobials are available for use in foodproducing animals (see Table I ) and the mechanisms of resistance are very diverse. The Given the large number of antimicrobials and the diversity of resistance mechanisms, it has not been possible to cover all aspects and to deal with all issues. It was decided to concentrate greatest attention on the main issues in order to understand the complex phenomenon of antimicrobial resistance in animals, while presenting updated and more precise information on specific aspects.
The reader will find general information on antimicrobial use, antimicrobial resistance and its consequences, and possible actions to contain antimicrobial resistance. More detailed papers provide comprehensive descriptions of antimicrobial resistance mechanisms. This issue of the Review also addresses risk analysis and the work of international organisations.
It was not possible to review in detail issues of antimicrobial resistance in particular species or the role of the environment in antimicrobial resistance. However, it is believed that the articles included in this review provide an excellent updated overview of the major issues linked to antimicrobial resistance in animal and public health. 
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